PBI16 COST ANALYSIS OF TWO TREATMENTS BY INFLIXIMAB (ORIGINATOR AND BIOSIMILAR) FOR PATIENTS WITH RHUMATOÏD ARTHRITIS (RA) OR INFLAMMATORY BOWEL DISEASE (IBD) IN A GROUP OF FRENCH PUBLIC HOSPITALS (UNIHA)
Abstract
Authors
F. Petiteau Moreau C. Hadjadj M. Feuillerat